Viewing Study NCT05665595

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:49 PM
Ignite Modification Date: 2026-01-21 @ 11:53 AM
Study NCT ID: NCT05665595
Status: COMPLETED
Last Update Posted: 2025-10-15
First Post: 2022-12-16
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD1, PD-1) View
None T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains … View